These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 32819114)
1. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting. Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114 [TBL] [Abstract][Full Text] [Related]
2. Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting. Dawood S; Konstantionva M; Dent R; Perazzo F; Kim SB; Villarreal-Garza C; Franco S; Dai MS; Simon S BMC Proc; 2021 Aug; 15(Suppl 10):15. PubMed ID: 34372853 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366 [TBL] [Abstract][Full Text] [Related]
4. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Wang X; Shi Y; Huang D; Guan X Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916 [TBL] [Abstract][Full Text] [Related]
5. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
6. New agents for the management of resistant metastatic breast cancer. Anampa J; Sparano JA Expert Opin Pharmacother; 2017 Dec; 18(17):1815-1831. PubMed ID: 29171761 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210 [TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Luo L; Keyomarsi K Expert Opin Investig Drugs; 2022 Jun; 31(6):607-631. PubMed ID: 35435784 [TBL] [Abstract][Full Text] [Related]
9. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598 [TBL] [Abstract][Full Text] [Related]
11. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study. Miller RS; Mokiou S; Taylor A; Sun P; Baria K Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731 [TBL] [Abstract][Full Text] [Related]
12. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Tazzite A; Jouhadi H; Benider A; Nadifi S Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831 [TBL] [Abstract][Full Text] [Related]
13. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476 [TBL] [Abstract][Full Text] [Related]
14. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy. Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653 [TBL] [Abstract][Full Text] [Related]
15. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States. Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978 [TBL] [Abstract][Full Text] [Related]
16. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors. Vaid AK; Deshmukh C; Rohatgi N; Ghosh J Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197 [TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Collet L; Péron J; Penault-Llorca F; Pujol P; Lopez J; Freyer G; You B Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158866 [TBL] [Abstract][Full Text] [Related]
18. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M; Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662 [TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study. Quek RGW; Mardekian J Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571 [TBL] [Abstract][Full Text] [Related]
20. Landmark trials in the medical oncology management of metastatic breast cancer. Lu P; Santa-Maria CA; Ballinger TJ; Sheng JY Semin Oncol; 2021 Jun; 48(3):246-258. PubMed ID: 34364700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]